We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Canopy Growth Corporation (CGC) Dipped More Than Broader Market Today
Read MoreHide Full Article
In the latest close session, Canopy Growth Corporation (CGC - Free Report) was down 5.55% at $0.98. The stock trailed the S&P 500, which registered a daily loss of 0.07%. Elsewhere, the Dow saw an upswing of 0.32%, while the tech-heavy Nasdaq depreciated by 0.51%.
Coming into today, shares of the company had lost 8.77% in the past month. In that same time, the Medical sector lost 2.17%, while the S&P 500 gained 5.58%.
Analysts and investors alike will be keeping a close eye on the performance of Canopy Growth Corporation in its upcoming earnings disclosure. The company's earnings report is set to go public on May 29, 2026. In that report, analysts expect Canopy Growth Corporation to post earnings of -$0.06 per share. This would mark year-over-year growth of 93.62%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $53.26 million, up 17.56% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of -$0.36 per share and a revenue of $210.58 million, demonstrating changes of +87.92% and +8.94%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Canopy Growth Corporation. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Canopy Growth Corporation is currently a Zacks Rank #2 (Buy).
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 156, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Canopy Growth Corporation (CGC) Dipped More Than Broader Market Today
In the latest close session, Canopy Growth Corporation (CGC - Free Report) was down 5.55% at $0.98. The stock trailed the S&P 500, which registered a daily loss of 0.07%. Elsewhere, the Dow saw an upswing of 0.32%, while the tech-heavy Nasdaq depreciated by 0.51%.
Coming into today, shares of the company had lost 8.77% in the past month. In that same time, the Medical sector lost 2.17%, while the S&P 500 gained 5.58%.
Analysts and investors alike will be keeping a close eye on the performance of Canopy Growth Corporation in its upcoming earnings disclosure. The company's earnings report is set to go public on May 29, 2026. In that report, analysts expect Canopy Growth Corporation to post earnings of -$0.06 per share. This would mark year-over-year growth of 93.62%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $53.26 million, up 17.56% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of -$0.36 per share and a revenue of $210.58 million, demonstrating changes of +87.92% and +8.94%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Canopy Growth Corporation. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Canopy Growth Corporation is currently a Zacks Rank #2 (Buy).
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 156, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.